Compare BioNTech SE - ADR (BNTX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Raymond James Financial, Inc. — how do they compare? BioNTech SE - ADR trades at $92.94 (market cap $23.31B), while Raymond James Financial, Inc. trades at $179.97 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.
| BNTX | RJF | |
|---|---|---|
Market Cap | $23.31B | $34.63B |
Sector | Health | Financials |
52-Week High | $119.34 | $180.55 |
52-Week Low | $83.89 | $140.89 |
Enterprise Value | $6.60B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.
The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.
Raymond James Financial (RJF) trades at $181.18, up 1.17% with strong technical momentum including a golden cross formation. The company reported record Q3 2026 earnings of $3.14 per share, beating estimates by 7.2%, driven by 16% revenue growth to $3.93 billion. Analyst consensus remains positive with 44% buy ratings and a $183.75 price target, slightly above current levels. The stock shows bullish moving average signals while RSI indicates potential overbought conditions near-term.
RJF demonstrates solid fundamental growth with consistent earnings beats and expanding profit margins, though valuation appears fair at current levels. Key risks include market sensitivity to capital markets performance and competitive advisor recruitment landscape. The technical setup suggests near-term resistance around $182, while fundamental strength supports longer-term upside potential if revenue momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
